Background & Aims: Staphylococcus aureus is one of the most common pathogens in nosocomial infections. Vancomycin is the most important therapeutic drug of choice for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) strains. Therefore, vancomycin-resistant Staphylococcus aureus (VRSA) or vancomycin-intermediate Staphylococcus aureus (VISA) strains are warning...

We address the black-box issue of VR sickness assessment (VRSA) by evaluating level physical symptoms sickness. For contents inducing similar level, can vary depending on characteristics contents. Most existing VRSA methods focused assessing overall score. To make better understanding sickness, it is required to predict and provide major rather than degree In this paper, we degrees main affecti...

Methicillin-resistant Staphylococcus aureus has been a major problem in the worldwide health care centres and institutions since the last 60 years . It has been a major pathogen responsible for nosocomial infections and recently has created life-threatening situations. Penicillin resistance was seen a few years after the drug was introduced. To solve this problem another drug of the penicillin ...

The merit of a scientific writing is high only when it disseminates the new knowledge in a universally accepted and logical manner. I, with great interest, have read a paper entitled “Bacteriology and antimicrobial susceptibility of adult chronic dacryocystitis” by Chaudhary et al (2010). This paper of writing has raised few concerns after reading it and compelled me to bring the issues to the ...

BACKGROUND & OBJECTIVES Multidrug resistant methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of nosocomial and community acquired infections and is on the rise. The glycopeptide vancomycin has been proposed as the drug of choice for treating such infections. The present study aimed at identifying the vancomycin resistance both phenotypically and genotypically among the MRSA i...

Intravenous vancomycin was approved in 1991 in Japan and has been widely used for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Consequently, ever since the initial discovery of vancomycin intermediate-resistant S. aureus in Japan, the vancomycin resistance of this organism has been a great concern in clinical settings. We investigated whether vancomycin ...

Staphylococcus aureus is a cause of hospital- and community-acquired infections. In 1996, the first clinical isolate of S. aureus with reduced susceptibility to vancomycin was reported from Japan. The vancomycin minimum inhibitory concentration (MIC) result reported for this isolate was in the intermediate range (vancomycin MIC=8 microg/mL) using interpretive criteria defined by the National Co...

The peptidoglycan compositions of vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50 (MIC 8 mg/L) and hetero-VRSA strain Mu3 (MIC 3 mg/L) were compared in order to understand the mechanism of vancomycin resistance. As compared with Mu3, the cell wall of Mu50 had increased amounts of glutamine-non-amidated muropeptides and decreased cross-linking of peptidoglycan with a greatly decrea...

Cryptotanshinone (CT), a major tanshinone of medicinal plant Salvia miltiorrhiza Bunge, demonstrated strong antibacterial activity against clinic isolated methicillin and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) in this experiment. The CT was determined against clinic isolated MRSA 1-16 with MIC and MBC values ranging from 4 to 32 and 8 to 128  μ g/mL; for MSSA 1-2 from 16 to ...